Braxia Scientific Corp., (CSE:BRAX) (OTC:BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announced the filing of its financial statements and management discussion and analysis for the second quarter ended September 30, 2022.

"We are executing our vision to increase access to novel treatments such as Ketamine and Psilocybin to address mental health disorders such as depression, anxiety, bipolar disorder, and post-traumatic stress disorder (PTSD)," saidDr. Roger McIntyre, CEO of Braxia Scientific.

Q2 2023 Financial Summary

• Q2 2023 in-clinic treatments increased 34.5% year-over-year. In the first 6 months of...